ALFA Finder
20:05 IST
BSE
Earnings Call
Aurobindo Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹10,263 Cr (+23.9% YoY), record EBITDA ₹2,156 Cr at 21.0% margin, PAT ₹1,124 Cr (+32.5% YoY). Lannett acquisition completed.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd news stories on ALFA NewsRead the news →- Share price
- ₹1,827.50
- Market cap
- ₹1,06,141 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.2×Sector 43.8×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Merger & Restructuring 5Business Update 5Acquisition 5Product Launch 2Earnings Call 2Results Update 1Regulatory Approval 1Other Announcement 1Management Change 1Legal & Regulatory 1Financial Results 1Dividend 1Board Meeting Date 1Annual General Meeting 1
Time
2 announcements with these filters
17:59 IST
BSE
Earnings Call
Aurobindo Pharma Earnings Call Transcript: Key Takeaways
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
- Call
- Guides 10% growth